Open AccessSTAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs
Author(s) -
Aditya Sharma,
Ravimohan Mavuduru,
Girdhar S. Bora,
Sudheer Kumar Devana,
Shrawan Kumar Singh,
Arup Kumar Mandal
Publication year - 2018
Publication title -
indian journal of urology/indian journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.333
H-Index - 30
eISSN - 1998-3824
pISSN - 0970-1591
DOI - 10.4103/iju.iju_378_17
Subject(s) - medicine , docetaxel , abiraterone , prostate cancer , oncology , androgen deprivation therapy , clinical trial , randomized controlled trial , cancer , hormone therapy , chemotherapy , breast cancer , androgen receptor
With the emergence of recent landmark trials, the treatment for hormone-sensitive metastatic prostate cancer (hsMPC) is changing from androgen deprivation therapy (ADT) alone to combination therapy. Both, docetaxel chemotherapy and abiraterone in addition to ADT have been extensively studied in well-conducted randomized controlled trials and were shown to improve outcomes. However, this paradigm shift in the treatment has also raised some queries. This mini review reflects upon the four landmark trials and tries to provide some perspective about the decision-making process for the patients with hsMPC.